Yaz Blood Clot Settlements Top $1.4B, Thousands of Cases Remain

Bayer is reporting that it has paid out at least $1.4 billion to settle more than 6,700 Yaz lawsuits and Yasmin lawsuits that alleged users suffered a pulmonary embolism, deep vein thrombosis or other blood clot-related injury. However, the drug maker continues to face thousands of additional cases involving the birth control pills that have not yet resolved.  

According to information disclosed in a second-quarter financial report, Bayer states that there are about 5,400 product liability lawsuits involving Yaz or Yasmin that have not yet been settled.

The $1.4 billion reported only includes Yaz and Yasmin settlements reached in cases involving a venous clot injury, which are being resolved after a case-specific review of medical records on a rolling basis.

Learn More About

Whistleblower Lawsuits

In addition to the blood clot settlements, Bayer has also agreed to pay up to $24 million to settle lawsuits involving gallbladder injuries associated with the use of Yaz or Yasmin. As of July 8, the drug maker reports that about 8,800 women who filed a Yaz gallbladder case have decided to participate in the settlement, which means that the required 90% participation rate has been med by plaintiffs to allow that deal to go forward.

Of the remaining 5,400 cases that have not been settled, Bayer estimates that about half of the cases involve Yaz blood clot injuries, such as a pulmonary embolism or deep vein thrombosis. The drug maker is continuing to consider settling such lawsuits on a case-by-case basis.

All of the claims involve similar allegations, claiming that Bayer failed to adequately research the potential side effects of Yaz and Yasmin, or warn about the increased risk of blood clots compared to certain older birth control pills.

The popular birth control pills contain the fourth-generation progestin drospirenone, which has been linked to a substantially higher blood clot risk. However, initial warnings provided to women using Yaz and Yasmin failed to adequately reflect this risk, according to allegations raised by thousands of former users.

In the federal court system, the Yaz and Yasmin litigation has been consolidated as part of an MDL in the Southern District of Illinois, which grew at one point to become the largest consolidated litigation in the United States, with the total number of active cases surpassing the asbestos litigation last year.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.